Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-9081 in Advanced Solid Tumours
NCT05582850Phase 1Terminated
- Sponsor
- Domain Therapeutics
- Start
- Nov 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of DT-9081 in solid tumor, sponsored by Domain Therapeutics. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Nov 2022; status: terminated.
02
Drugs
DT-9081
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05582850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582850.